LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc (AGEN). (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the ...

Authorized access interest continues to expand across regions Phase 3 BATTMAN trial commenced patient enrollment in April 2026, advancing BOT+BAL into pivotal evaluation Zydus collaboration closed in ...